INTRODUCTION Gastric cancer is one of the most common cancers worldwide. Its incidence varies according to its geographic region, being more common in East Asia, Eastern Europe and South America. About 70% of gastric neoplasms occur in developing countries. Globally, it is estimated that in 2018
Rationale: The purpose of this study is to combine PTK-787, a potent orally vascular endothelial growth factor (VEGF) receptor inhibitor (in disorders where VEGF is known to be involved in the pathophysiology), with Imatinib mesylate (IM), a protein-tyrosine kinase inhibitor of abl, Bcr-Abl,